FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年5月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 百濟神州有限公司 (根據瑞士法律註冊成立的公司) 呈交日期: 2025年6月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06160 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 9,500,000,000 | USD | 0.0001 | USD | | 950,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 9,500,000,000 | USD | 0.0001 | USD | | 950,000 | 備註： | ...

Group 1 - The pharmaceutical sector has recently experienced a significant pullback, with the innovative drug concept seeing a net outflow of nearly 2.5 billion yuan in A-shares [1] - The Tianhong Innovative Drug ETF (517380) reached a new high for the year before experiencing a substantial decline, dropping 2.75% with a trading volume of 22 million yuan, and most constituent stocks fell nearly 5% [1] - The Tianhong Innovative Drug ETF is the only product tracking the Hang Seng-Hu-Shen-Hong Kong Innovative Drug Selected 50 Index, which includes leading innovative drug companies from the three markets [1] Group 2 - Dongwu Securities predicts that 2025 will mark the explosive growth of China's innovative drug industry, driven by three core factors: significant BD transactions, profitability turning points for leading companies, and an improving policy environment [2] - Guosheng Securities acknowledges short-term trading pullback risks but emphasizes the solid underlying logic and clear trends in the innovative drug sector, maintaining a positive outlook for the innovative drug bull market [2] - The market size of China's innovative drugs is expected to exceed 2 trillion yuan by 2030, with a compound annual growth rate of 24.1% [2]

Investment Rating - The report rates the innovative drug industry positively, indicating a significant growth potential and favorable market conditions for investment. Core Insights - The year 2025 is projected to be the starting point for at least three years of favorable market conditions for innovative drugs, driven by several key factors including high upfront payments for collaborations and improved domestic clinical environments [4]. - The Chinese innovative drug market is expected to experience rapid growth, with a projected market size of nearly 550 billion RMB in 2024 and an estimated CAGR of 24.1%, potentially exceeding 20 trillion RMB by 2030 [4][10]. - The research and development capabilities of Chinese companies have significantly improved, with a notable increase in the number of original FIC innovative drugs, positioning China as a global leader in certain therapeutic areas [4][27]. - The number and value of license-out transactions for Chinese innovative drugs have reached new highs, with 94 transactions in 2024 totaling 51.9 billion USD, reflecting a 26% year-on-year increase [4][46]. - The overall revenue of innovative drug companies is steadily increasing, with A-share companies projected to grow from 30.07 billion RMB in 2018 to 62.8 billion RMB in 2024, indicating a transition from high investment phases to profitability [4][18]. Summary by Sections 1. Market Outlook - The innovative drug market in China is set for explosive growth, with a total market size projected to reach 20 trillion RMB by 2030, representing a 264% increase from 2024 [10][4]. - The domestic innovative drug market is currently only 3% of the global market, indicating substantial growth potential [10]. 2. R&D Strength - Chinese companies have made significant advancements in R&D, with 41% of global innovative drug targets covered by domestic firms [27]. - The number of original FIC innovative drugs from Chinese companies surpassed that of Europe in 2021, ranking second globally [27]. 3. License-Out Transactions - The license-out transactions for Chinese innovative drugs have seen a remarkable increase, with 94 transactions in 2024 and a total transaction value of 51.9 billion USD [46][41]. - The trend of license-out transactions is expected to continue growing, with a projected total of 2.659 billion USD by 2030 [10]. 4. Revenue Growth - A-share innovative drug companies are expected to see their revenues grow significantly, with a projected increase to 62.8 billion RMB by 2024 [18]. - The overall profitability of innovative drug companies is improving, with several companies expected to turn profitable by 2025 and 2026 [4]. 5. Technological Advancements - The report highlights the emergence of advanced therapies such as ADCs and dual-target antibodies, suggesting a focus on high-tech innovations in the industry [4]. - The ASCO conference showcased a record number of presentations from Chinese companies, indicating the growing influence of Chinese innovations in global markets [4].

除了电子设备和仪器、集成电路，医疗保健、工业机械、电子元件等板块也获得了较多外资机构的关 注。百济神州、汇川技术、新产业、深南电路等行业龙头接受外资调研的次数位居前列。 ◎记者 王彭 据统计，5月以来，200余家外资机构现身A股上市公司调研名单，累计调研逾500次。具体而言，以电 子设备和仪器、集成电路为代表的硬科技领域是外资关注的焦点。 Wind数据显示，截至6月4日，5月以来共有222家外资机构调研了185家A股公司，累计调研532次。在这 份调研名单上，高盛、富达、贝莱德、瑞银、安联、Point72等机构频频现身。在接受外资机构调研的 行业中，代表硬科技领域的电子设备和仪器、集成电路等板块获得最多外资机构的关注。据统计，奥普 特、澜起科技、沪电股份、奥比中光等公司均吸引了30家以上外资机构的调研。 以澜起科技为例，公司5月29日披露了一份投资者关系活动记录表，瑞银、安联、富达、Point72等知名 外资机构均现身调研名单；沪电股份近日披露的投资者关系活动记录表显示，贝莱德、富达、高盛、摩 根大通等外资机构参与了公司5月19日的特定对象调研。 被称为"华尔街最疯狂的赚钱机器"的Point72在此期间调研1 ...

6月4日，富时罗素公布2025年6月富时中国50指数、富时中国A50指数、富时中国A150指数、富时中国A200指数以及富时中国A400指数季检结 果，该变更将于6月20日星期五收盘后生效。 据了解，富时罗素在选股的时候，一般都是根据专业分析、实地考察以及过往的盈利能力作为准则，因此被富时罗素"青睐"的公司在过去的一年经营情况在A股范 围内也是个中翘楚。 富时中国A50指数纳入江苏银行 富时中国A50指数此次将江苏银行纳入，剔除长城汽车，同时将百济神州、伊利股份、上汽集团、赛力斯、汇川技术等纳入备选名单。 富时中国A50指数由富时罗素编制并发布。该指数由上海和深圳证券交易所市场中总市值最大的50只股票组成，反映A股市场中最具影响力的前50大上市公司股票的 表现，不少国际投资者把这一指数看作是衡量中国市场的精确指标。 | 证券代码 | 证券简称 | | --- | --- | | 600919 | 江苏银行 | | | 富时中国A50指数剔除名单 | | 证券代码 | 证券简称 | | 601633 | 长城汽车 | | | 富时中国A50指数备用名单 | | 证券代码 | 证券简称 | | 688235 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2025年5月30 日，董事會薪酬委員會根據2016期權及激勵計劃的條款向二名承授人授出可認 購合共21,140股美國存託股份的購股權並向三百六十八名承授人授出涉及合共 54,538股美國存託股份的受限制股份單位。 2016期權及激勵計劃項下的購股權 於2025年5月30日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予二名 承授人可認購合共21,140股美國存託股份的購股權。 授出購股權詳情 購股權詳情如下： 授出日期： 2025年5月30日 承授人數目： 二名 授出購股權及受限制股份單位 已授出購股權涉及的相關股份數目： 274,820 購股權總數（美國存託股份）: 21,140 因已授出購股權獲行使而可予 ...

Group 1 - The market experienced a rebound on June 4, with the ChiNext Index leading the gains. The total trading volume in the Shanghai and Shenzhen markets reached 1.15 trillion yuan, an increase of 11.6 billion yuan compared to the previous trading day [1] - The innovative drug concept remained active, with the Tianhong Innovative Drug ETF (517380) closing up 2.34%, reaching a peak price of 0.660 yuan, the highest since November 2023, and achieving a trading volume of nearly 20 million yuan, a two-year high [1] - The Tianhong Innovative Drug ETF (517380) has seen a year-to-date increase of 25.96% as of June 4, ranking first among all industry ETFs in the market [1] Group 2 - Changjiang Securities indicated that the valuation level of domestic innovative drugs is low, and some products have the potential to be the best in their class globally, supporting the outlook for innovative drugs to expand internationally and achieve premium valuations [2] - Guojin Securities emphasized that innovative drugs and certain semi-innovative drugs are key investment focuses, with upcoming policy changes and data releases expected to catalyze stock price movements [2] - Huafu Securities reported that the total transaction amount for innovative drug BD from 2020 to 2024 increased from 9.2 billion USD to 52.3 billion USD, with the upfront payment amount rising from 600 million USD to 4.1 billion USD [2]

6月4日，创新药概念继续活跃，相关ETF中，创新药ETF天弘(517380)截至发稿涨2.81%，盘中价格最 高触及0.660元，创2023年11月以来新高。成分股中，信达生物涨超15%，皓元医药、泰格医药、中国 生物制药等涨幅均在6%以上。 消息面上，据新华社消息，2025年1至5月，国家药品监督管理局批准20余款1类创新药上市，数量刷新 近五年同期纪录；2025年美国临床肿瘤学会（ASCO）年会上，70余项中国原创研究成果入选。近来， 国内创新药上市跑出加速度，药企源头创新与国际竞争力同步跃升。业内人士认为，我国创新药领域已 从过去的"跟随式创新"逐步迈向"全球领跑"。中国药企紧紧围绕临床价值核心，在肿瘤靶向、免疫治疗 等关键赛道发力，正悄然改写全球医药格局。 中邮证券认为，创新药板块近期具备较多催化，海外BD、ASCO大会等事件持续提高板块热度。国内 创新药企迎来估值重塑，有望成为贯穿全年的投资主线。下半年国家医保谈判为重要事件，谈判前成功 获批上市创新药有望通过国谈进入医保实现加速放量。 （本文机构观点来自持牌证券机构，不构成任何投资建议，亦不代表平台观点，请投资人独立判断和决 策。） 拉长时间来看， ...

Group 1 - The Chinese innovative pharmaceutical industry is experiencing an unprecedented revaluation, with the innovative drug index rising over 20% and the Hong Kong innovative drug index increasing by more than 45% this year [1][2] - Institutions have shown heightened interest in the innovative drug sector, with numerous companies such as BeiGene and I-Mab being heavily researched by various institutions [1][3] - The focus of institutional research has shifted from generic drugs and raw materials to cutting-edge areas like ADCs, bispecific antibodies, and cell therapies, indicating a growing interest in clinical data and international progress [4][5] Group 2 - The recent surge in the innovative drug sector is attributed to the culmination of years of investment and development, with many projects now reaching commercialization [5][6] - The improvement in liquidity and the influx of foreign capital have significantly boosted the performance of Hong Kong innovative drug stocks, with net purchases exceeding 600 billion yuan this year [6][7] - The next three years are expected to be critical for the Chinese innovative drug industry, with 2025 marking a pivotal year for revenue growth, profitability, and valuation increases [8][9] Group 3 - The innovative drug sector is anticipated to remain a key focus within the pharmaceutical industry, with particular attention on companies that are successfully entering overseas markets and those that are experiencing significant domestic sales growth [9]

Summary of Key Points Core Viewpoint - The June stock recommendations from 42 brokerage firms show a significant increase in the number of recommended stocks, with the pharmaceutical and biotechnology sector returning to the top of the industry recommendation rankings after three years, indicating a renewed market interest in cyclical industries [1][3]. Stock Recommendations - A total of 332 stocks received 457 recommendations, with 42 stocks from the ChiNext gaining 53 recommendations, 45 stocks from the STAR Market receiving 59 recommendations, and 43 Hong Kong stocks getting 62 recommendations, marking an increase of 6 and 7 stocks respectively compared to the previous month [1]. - Six stocks received recommendations from five brokerage firms: China Merchants Bank, Yara International, Smoore International, SF Holding, Qingdao Beer, and Haida Group [1]. - Six stocks received recommendations from four brokerage firms: Zijin Mining, China Mobile, Zhenhua Heavy Industries, Tencent Holdings, Hangzhou Bank, and Dongpeng Beverage [1]. Industry Rankings - The pharmaceutical and biotechnology sector achieved a recommendation rate of 10.2%, reclaiming the top position, while the electronics sector fell to second place with a recommendation rate of 9.3% [3]. - The food and beverage sector ranked third with a recommendation rate of 6.58%, and the machinery equipment sector ranked fourth with a rate of 6.35% [3]. - The coal industry saw a significant increase in recommendation rate by 59.6%, while the transportation sector increased by 52.1%, indicating a positive outlook for these industries [3]. Declining Industry Interest - The retail trade sector experienced a notable decline in recommendation rate by 43.17%, attributed to renewed trade tensions and previous excessive price increases [4]. - The defense and military industry saw a decrease of 34.77%, mainly due to the easing of the Russia-Ukraine situation [4]. - The automotive sector's recommendation rate dropped by 30.99%, reflecting concerns over industry competition [4]. Performance of Brokerage Recommendations - In May, 30 out of 45 brokerage firms reported positive returns, with the top performers being Guoyuan Securities (6.28%) and Caitong Securities (5.93%) [5][6]. - As of May 30, 36 out of 45 brokerage firms had positive returns for the year, with 16 firms achieving returns close to or exceeding 10% [6]. Market Outlook - Analysts suggest that June will see continued improvement in returns and win rates, with a focus on large-cap growth stocks, although the market is expected to remain volatile [7]. - The market sentiment has been affected by fluctuating U.S. tariff policies and slow progress in U.S.-China trade negotiations, which are key factors influencing market risk appetite [7].